TD Cowen raised the firm’s price target on Procept BioRobotics to $99 from $75 and keeps a Buy rating on the shares. The firm said the recent 30% stock appreciation following its FDA approval is justified in their view, since Hydros can spark a multiyear new product cycle that enhances the current revenue growth trajectory.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- BTIG medical technology analyst holds an analyst/industry conference call
- Procept BioRobotics price target raised to $95 from $74 at Truist
- PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
- Procept BioRobotics management to meet with Truist
- Procept BioRobotics price target raised to $94 from $80 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue